For example, levels of the IGF ligands predict benefit from the IGF-1R monoclonal antibody ganitumab in pancreas cancer [4] supporting the idea that receptor activation is an important predictive biomarker for anti-IGF-1R drugs. This evidence concerns the gene IGF1 and pancreatic neoplasm.